What changed: Tenosynovial giant cell tumour (TGCT)

When this page itself was last checked or edited.

Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025

Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity

FDA approval 14 February 2025 for symptomatic TGCT where surgery would worsen function.

ORR 40% vs 0%.

Gelderblom and colleagues, Lancet.

Marginal excision; recurrence is uncommon and re-excision is curative in most cases.

Hepatotoxicity judged to outweigh benefit for a non-lethal disease.

Symptomatic tenosynovial giant cell tumour not amenable to surgery

Week 25 RECIST response 39% vs 0% (placebo); FDA approval 2019 with a liver-toxicity REMS.

First systemic therapy approved for TGCT (August 2019), with a boxed hepatotoxicity warning.

Tap and colleagues, NEJM: high response rate in diffuse TGCT.

West and colleagues show a CSF1-expressing neoplastic minority recruits the macrophage majority (PNAS).

A milestone in how this cancer is treated.